Lori W Charette, AUDIOLOGIST Audiologist Medicare: Not Enrolled in Medicare Practice Location: Gaylord Farm Rd, Wallingford, CT 06492 Phone: 203-284-2800 Fax: 203-294-3294 |
Best Life Hearing Center, Llc Audiologist Medicare: Medicare Enrolled Practice Location: 850 N Main Street Ext Ste 1c, Wallingford, CT 06492 Phone: 860-919-0998 |
Genm Senior Care Consulting Group Llc Audiologist Medicare: Medicare Enrolled Practice Location: 67 Masonic Ave, Wallingford, CT 06492 Phone: 203-678-7857 |
Dr. Amanda Ottochian-tripp, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 31 Algonquin Dr, Wallingford, CT 06492 Phone: 203-213-4426 |
Susan J. Chin, CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 85 Barnes Rd, Suite 207, Wallingford, CT 06492 Phone: 203-678-1201 Fax: 203-678-1209 |
Ct Audiology Partners Audiologist Medicare: Medicare Enrolled Practice Location: 850 N Main Street Ext Ste 2a2, Wallingford, CT 06492 Phone: 203-626-5581 |
Ms. Hillary H Lewis Audiologist Medicare: Medicare Enrolled Practice Location: 22 Masonic Ave, Audiology Department, Wallingford, CT 06492 Phone: 203-679-6272 |
News Archive
The Food Standards Agency is advising people not to eat a type of seaweed called hijiki because of the high levels of arsenic that it contains.
Studies by researchers at Dominican University of California show that breast cancer cells become increasingly aggressive the longer they are exposed to small concentrations of cadmium, a heavy metal commonly found in cosmetics, food, water and air particles.
Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.
A recent US study, currently available on bioRxiv* preprint server, implies that vaccination with bacille Calmette-Guérin (BCG) can limit the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by targeting innate immune pathways and could thus be used as a platform for pinpointing early immunologic events affecting the outcome of coronavirus disease (COVID-19).
› Verified 3 days ago